Antidepressants compared to placebo for people with binge eating disorder: A systematic review and meta-analysis

• Published in: European neuropsychopharmacology 2024-07, Vol.84, p.5-15
• Main Authors: Sioziou, Angeliki L., Lappas, Andreas S., Skarlatos, Menelaos, Mesiari, Christina, Florou, Maria C., Argyrou, Aikaterini, Christodoulou, Nikos, Chourdakis, Michail, Samara, Myrto
• Format: Article
• Language: English
• Subjects: Antidepressive Agents - adverse effects; Antidepressive Agents - therapeutic use; Binge eating episodes; Binge-Eating Disorder - drug therapy; Binge-Eating Disorder - psychology; Eating disorders; Humans; Medication; Pharmacotherapy; Randomized Controlled Trials as Topic - methods; Therapy; Treatment; Treatment Outcome
• ISSN: 0924-977X; 1873-7862; 1873-7862
• DOI: 10.1016/j.euroneuro.2024.03.006

Binge eating disorder (BED) is the most prevalent eating disorder. Treatment options include pharmacotherapy as well as psychotherapy, with the latter recommended as a first-line option. However, the use of psychotherapeutic interventions poses several challenges. Antidepressants are easily accessible, but they lack robust evidence-base. This systematic review aims to comprehensively examine the efficacy and safety of antidepressants for the treatment of BED. Five databases were searched for randomized controlled trials (RCTs) comparing antidepressants vs. placebo in BED until 23/11/2023. Pairwise meta-analytic evaluations were performed. The primary outcomes were remission and binge eating frequency. Secondary outcomes were response to treatment, eating psychopathology, depression, anxiety, body weight, Body Mass Index (BMI), all-cause discontinuation, discontinuation due to adverse effects and total adverse events. Sixteen RCTs with a total of 984 participants were meta-analysed. Antidepressants were more effective than placebo in achieving remission (RR: 1.39, 95 % CI: 1.04 to 1.86) and in reducing binge eating episodes (SMD: -0.29, 95 % CI: -0.51 to -0.06). Similarly, in the secondary outcomes of response and depression, antidepressants demonstrated superiority over placebo. Antidepressants appear to be effective in reducing symptoms of BED. Small samples and effect sizes hinder the generalizability and clinical utility of these results. There is a lack of follow-up findings regarding the maintenance of effects. There is a pressing need for more RCTs examining antidepressants and other types of pharmacotherapy. Future research should include larger number of participants and increase the duration of follow-up.